Postoperative delirium is common after hip fracture surgery, and may have a neuro-inflammatory cause. We conducted a single-centre, randomised, double-blind, placebo-controlled trial of 117 older hip fracture patients to see if a single, pre-operative intravenous dose of 125 mg methylprednisolone could reduce the severity and/or incidence of postoperative delirium, assessed using the Confusion Assessment Method delirium severity score. Modified intention-to-treat analysis found no significant difference in our primary outcome, median ( , p = 0.008) were significantly lower in the methylprednisolone compared with the placebo group. There were no significant between-group differences in the rate of completing physiotherapy, postoperative pain, the administration of antipsychotic drugs, infection, length of inpatient stay or 30-and 90-day mortality. No major adverse reactions related to methylprednisolone were recorded. We conclude that a single, pre-operative dose of 125 mg methylprednisolone does not reduce the severity of postoperative delirium, but may reduce both the prevalence of delirium and the severity of fatigue after hip fracture surgery in older patients, enabling remobilisation and recovery.
Introduction
Postoperative delirium (POD) is a common complication among elderly patients after hip fracture surgery [1] , with a reported incidence as high as 62% [2, 3] , depending on the diagnostic criteria used. Postoperative delirium is associated with increased morbidity and mortality, and impaired functional recovery [1, [4] [5] [6] .
Currently, no recommended pharmacological prophylaxis exists to prevent POD [7, 8] . A recent meta-analysis concluded that there is no evidence to support the use of antipsychotics for prevention or treatment of POD [9] . Neuro-inflammation induced by physiological stress appears to contribute to the multifactorial but poorly understood aetiology of the condition [1, 3, 10] . Elderly individuals are susceptible to the stress response caused by both the initial trauma of the fracture and subsequent restorative surgery [11] [12] [13] [14] .
Glucocorticoids are used as peri-operative anti-emetics [15] [16] [17] [18] , and can reduce pain, fatigue and recovery time after elective surgical procedures [15-17, 19, 20] . However, no studies have assessed the impact of glucocorticoids on POD after hip fracture surgery, possibly for fear of actually inducing psychosis and delirium [21] . We hypothesised that a single, pre-operative, high dose of intravenous methylprednisolone (125 mg) given on admission to hospital might result in a reduced incidence of POD, and might also improve pain and fatigue, postoperatively compared with placebo in elderly patients after a hip fracture.
Methods
Our randomised, double-blind, placebo-controlled study was approved by our regional ethics committee, the Danish Health and Medicines Authority and the Danish Data Protection agency.
The study was conducted at the Copenhagen University Hospital, Hvidovre, Denmark between December 2014 and May 2016. All patients admitted acutely after hip fracture were eligible for inclusion into the study if they could speak and understand Danish, could provide informed oral and written consent, were aged ≥ 65 years of age and had a Danish social security number. Exclusion criteria included: allergy to methylprednisolone; active peptic ulcer disease; cancer; glaucoma; insulin-dependent diabetes mellitus; positive human immunodeficiency virus, hepatitis B or C virology; or immunoinflammatory disease (except topically treated skin disease and respiratory disease); inability to provide informed consent (e.g. severe dementia); or currently receiving systemic glucocorticoids or immunosuppressive therapy. All included patients provided oral and written informed consent before participation.
A computer-generated 1:1 randomisation list using the free Internet service www.randomization.com was generated by two nurses not otherwise involved in the study. One-hundred and twenty patients were assigned randomly to one of two equal-sized groups. Their allocation was concealed in 120 sequentially numbered and opaque envelopes determining active treatment or placebo. A standardised algorithm based on the type of fracture and patient age was used to determine the type of surgical procedure performed [22] .
All patients were admitted to our hip fracture unit and treated according to a standardised, enhanced recovery protocol; delirium was screened for daily, and Based on an institutional POD prevalence of 30% (unpublished data), an estimated mean daily (SD) CAM-S of 5.5 (2.7) in the placebo group [23] , and a 33% effect size variation between clinically significant groups, we calculated that 49 patients would need to be enrolled in each group (two-sided a error 0.05, power 0.9). To compensate for non-completion, 120 patients were enrolled in the trial.
The analytical framework was superiority, and all analyses were conducted as per the intention-to-treat principle and were performed blinded.
Outcome variables were assessed for normality of distribution by inspection of Q-Q plot, histograms of frequencies and the Kolmogorov-Smirnov test. The fit was not accepted for the primary outcome (cumulated median CAM-S). Therefore, the between-group difference for the primary outcome was evaluated by the non- 
Results
After exclusions (Fig. 1 ), 120 out of 718 patients screened for inclusion were randomly allocated to either methylprednisolone or placebo.
Patients' baseline characteristics and peri-operative data were similar between groups (Tables 1 and 2) .
No significant between-group difference was observed for our primary outcome (cumulative median CAM-S score in the first three postoperative days) (Table 3 ). There were significantly more patients with No major adverse reactions related to methylprednisolone were recorded.
Discussion
In this randomised, double-blind, placebo-controlled study, we found no between-group difference in the median CAM-S score, the study's primary outcome.
Significantly fewer instances of POD and fatigue occurred in patients receiving methylprednisolone compared with placebo, although our results should be interpreted with caution, as the study sample size was not powered to detect significant differences in these secondary outcomes and the result was only marginally statistically significant. We could not find significant differences between the groups in our other secondary outcomes.
Postoperative delirium is a major clinical concern, and currently, no pharmacological treatment exists to prevent or treat it [7] . The presence and duration of delirium have been associated with postoperative morbidity and mortality, prolonged length of stay, worsening cognitive function, poor functional recovery and nursing home placement [1, [4] [5] [6] . Our results suggest that a single dose of 125 mg methylprednisolone might decrease the incidence of POD and attenuate postoperative fatigue in elderly patients after hip fracture.
In the placebo group, the prevalence of POD (19/58 patients) was similar to the incidence previously recorded at our unit and in other hospitals [2, 3] . We used the long-form CAM-S score as a proxy measure of the prevalence and severity of POD in response to the physiological stress of surgery and anaesthesia. The CAM-S was created for clinical and research use, has been an integrated diagnostic tool in our ward for many years and can be used accurately by welltrained, non-physician research assistants [23, 27] . A CAM-S score of 5 or more indicates delirium or (importantly) subsyndromal delirium, and is associated with, if not diagnostic for, a poor postoperative outcome in older patients [23, 28, 29] . Subsyndromal delirium is phenotypically similar to delirium but does not meet the formal diagnostic criteria for the diagnosis [30, 31] being milder in severity, but is associated with poorer outcome, making it essential to identify [32] .
Early mobilisation after hip fracture surgery is vital for rapid recovery [33] . In combination, the lower incidences of delirium and fatigue suggest that a single dose of methylprednisolone may be a useful tool in enabling remobilisation, re-enablement and rehabilitation [34] , although we did not see any between-group differences in the ability to complete physiotherapy or length of stay. The reduction in postoperative fatigue we found is consistent with other studies of pre-operative single-dose glucocorticoid administration [35, 36] .
There were no major adverse reactions or increased incidence of infection in the methylprednisolone group.
High-dose glucocorticoids cause transient hyperglycaemia, and are associated with increased postoperative infection rates [18] , although recent evidence indicates their use is safe or even beneficial [18] [19] [20] ) in orthopaedic surgery [37] .
Elderly patients with hip fracture are fragile, and their complex, multidisciplinary, peri-operative care requires attention to details and avoidance of complications [2, 7, 38] . Single interventions rarely have a pivotal effect on outcome, unless they have a profound effect on patients'
pathology. Immunomodulation is reduced in the elderly, making them more vulnerable to the pathophysiological stress of trauma/surgery/anaesthesia [12] [13] [14] , particularly manifest as POD and cognitive dysfunction [1, 3, 10, 39] .
The results of our study suggest that methylprednisolone administration supports the attenuated anti-inflammatory response to stress that occurs in this patient group. In contrast to our findings, intra-operative high-dose steroids have been shown not to reduce either the incidence or the duration of early POD after cardiac surgery [40, 41] . This suggests that the efficacy of supplemental steroids may depend on the patient population, possibly benefitting older patients more, and the dosing regime used, possibly more beneficial if given prophylactically before surgical trauma.
There are several limitations to our study. Firstly, although we consider the study participants to be fairly representative of the general patient population with hip fracture, we were not allowed to include patients who had severe dementia, cognitive impairment or delirium before surgery, due to the Danish regulations regarding informed consent, thereby not including exactly the group of patients with the highest risk of developing POD [42] .
Secondly, patients received identical, rather than weight/BMI-dependent, doses of methylprednisolone, at non-standardised (and occasionally wide-ranging) times after trauma and before surgery. However, there were no statistical differences between groups in any of these variables, suggesting randomisation limited any effects.
Thirdly, we accept that our standard use of epidural anaesthesia may limit the applicability of our findings to 
